mv-slider
lazy: true
HOME
サブ-ナビゲーション
information
News
Corporate Guide
Business
Investor Relations
Sustainability
Contact Us
HOME
NEWS
What’s new
Press Release
Investor Relations
Information
2025/06/04
Redesign of the Regulatory Strategy for NY-ESO-1・siTCR™ Gene Therapy in Japan
2025/05/29
Notice of the 23rd Annual General Meeting of Shareholders
（198KB）
2025/05/13
Notice of Changes in Representative Directors
（140KB）
2025/05/13
Notice Concerning Dividend from Surplus
（137KB）
2025/05/13
Consolidated Financial Results for the FY Ended March 31 2025
（478KB）
Read More
2025/06/04
Redesign of the Regulatory Strategy for NY-ESO-1・siTCR™ Gene Therapy in Japan
2024/06/27
Takara Bio announces the business partnership with Gap Junction Therapeutics to develop AAV gene therapy for hereditary hearing loss
2023/11/13
Takara Bio Announces "SonuAAV™", a Novel AAV Vector for Efficient Gene Transfer to the Inner Ear Organ.
2023/10/12
Construction of the Center for Cell and Gene Processing III, which manufactures mRNA vaccine ingredients and enzymes for mRNA production
2023/10/05
Takara Bio Announces Publication of Results from NY-ESO-1・siTCR™ Gene Therapy Study in Clinical Cancer Research
Read More
2025/05/29
Notice of the 23rd Annual General Meeting of Shareholders
（198KB）
2025/05/13
Notice of Changes in Representative Directors
（140KB）
2025/05/13
Notice Concerning Dividend from Surplus
（137KB）
2025/05/13
Consolidated Financial Results for the FY Ended March 31 2025
（478KB）
2025/05/01
(Progress of Matters Previously Disclosed) Notice Concerning the Absorption-type Merger (Simplified Merger) of the Wholly Owned Subsidiary
（233KB）
Read More
2024/05/02
Takara Bio to Present Advances in Gene and Cell Research at ASGCT 2024
Read More
BUSINESS
Read More
Research reagents
Scientific instruments
CDMO
Gene Therapy
INVESTOR
RELATIONS
Read More
SUSTAINABILITY
Read More
COMPANY
Read More
PAGETOP
PAGETOP
CLOSE
MENU
サイト内検索
menu
JA
EN
contact
gnavi-box
